This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About SIMPONI® (golimumab)

Prescribing Information

SIMPONI (golimumab) is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day 1 for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (Nr-axSpA) and a 4-weekly dosing schedule for Ulcerative Colitis (UC).1

Gastroenterology

Find out how SIMPONI can help your patients with moderate-to-severe Ulcerative Colitis.

Find out more

Rheumatology

Find out how SIMPONI can help your patients with AS, PsA, nr-axSpA, and RA.

Find out more

SIMPONI indications:

SIMPONI is indicated for the treatment of:1

Psoriatic Arthritis (PsA)

Active and progressive PsA in adult patients when response to disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate, when used alone or in combination with methotrexate (MTX).1

Anklyosing Spondylitis (AS)

Severe, active AS in adults who have responded inadequately to conventional therapy.1

Ulcerative Colitis (UC)

Moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1

Rheumatoid Arthritis (RA)

Moderately to severely active RA in combination with methotrexate, when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.1

SIMPONI is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX.

Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).1

Want to keep up to date with the latest educational resources and events?

Register for more information

Patient support

Information for your SIMPONI patients

Patient support information leaflet
 

Our patient support website will help your patients:

  • Get started with SIMPONI
  • Self-dosing instructions
  • Safety information
  • Diet and exercise tips
Visit our patient website

Important safety information

References

  1. SIMPONI® (golimumab). Summary of Product Characteristics. Available at www.medicines.org.uk/emc.

Supporting documentation

SIMPONI 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Syringe | Patient Information Leaflet for Pre-filled Pen

SIMPONI 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Pen

GB-GOL-00271 | Date of Preparation: September 2020